New-onset systemic sclerosis and scleroderma renal crisis under docetaxel.
Véronique DebienArthur PetitdemangeDorothée BazinCarole EderleBenoit NespolaHamid MerdjiJérome OlagneThierry MartinAurélien GuffroyCarole PflumioPublished in: Journal of scleroderma and related disorders (2021)
Systemic sclerosis is a rare systemic autoimmune disease characterized by microvascular impairment and fibrosis of the skin and other organs with poor outcomes. Toxic causes may be involved. We reported the case of a 59-year-old woman who developed an acute systemic sclerosis after two doses of adjuvant chemotherapy by docetaxel and cyclophosphamide for a localized hormone receptor + human epithelial receptor 2-breast cancer. Docetaxel is a major chemotherapy drug used in the treatment of breast, lung, and prostate cancers, among others. Scleroderma-like skin-induced changes (morphea) have been already described for taxanes. Here, we report for the first time a case of severe lung and kidney flare with thrombotic microangiopathy after steroids for acute interstitial lung disease probably induced by anti-RNA polymerase III + systemic sclerosis after docetaxel.
Keyphrases
- systemic sclerosis
- interstitial lung disease
- drug induced
- locally advanced
- liver failure
- prostate cancer
- respiratory failure
- endothelial cells
- rectal cancer
- radiation therapy
- aortic dissection
- soft tissue
- squamous cell carcinoma
- wound healing
- high dose
- public health
- multiple sclerosis
- high glucose
- type diabetes
- rheumatoid arthritis
- intensive care unit
- young adults
- diabetic rats
- induced pluripotent stem cells
- benign prostatic hyperplasia
- electronic health record
- glycemic control